DILTIAZEM HYDROCHLORIDE

Post-LOE

diltiazem hydrochloride

Sagent Pharmaceuticals

ANDAINJECTIONINJECTABLE

Approved

Feb 1996

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

DILTIAZEM HYDROCHLORIDE (diltiazem hydrochloride) by Sagent Pharmaceuticals is clinical pharmacology mechanisms of action diltiazem inhibits the influx of calcium (ca) ions during membrane depolarization of cardiac and vascular smooth muscle. Approved for atrial fibrillation, atrial fibrillation. First approved in 1996.

Drug data last refreshed 1w ago

Mechanism of Action

CLINICAL PHARMACOLOGY Mechanisms of Action Diltiazem inhibits the influx of calcium (Ca) ions during membrane depolarization of cardiac and vascular smooth muscle. The therapeutic benefits of diltiazem in supraventricular tachycardias are related to its ability to slow AV nodal conduction time and…

Worked on DILTIAZEM HYDROCHLORIDE at Sagent Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

DILTIAZEM HYDROCHLORIDE

Mechanism of Action

Indications (1)